Ibex Investors’s Integra LifeSciences IART Stock Holding History

Ibex Investors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,034	Closed	-$389K	–	227
2018 Q2	$389K	Buy	+6,034	New	+$374K	0.22%	101

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ibex Investors's IART Position: Q3 2018 in Review

Ibex Investors sold out of Integra LifeSciences (IART) in Q3 2018, closing a stake of 6,034 shares — an estimated $389K sold.

Ibex Investors first reported a position in IART in Q2 2018 and held it in 1 quarter. The position peaked at $389K in Q2 2018. 249 funds tracked by Wall St. Rank hold IART as of Q3 2018.

Ibex Investors reported no remaining Integra LifeSciences position as of Q3 2018 after selling out during the quarter.
Ibex Investors sold 6,034 Integra LifeSciences shares in Q3 2018, an estimated $389K.
Ibex Investors first reported a position in Integra LifeSciences in Q2 2018 and held it in 1 quarter.
Ibex Investors's Integra LifeSciences position peaked at $389K in Q2 2018.
249 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2018.

Based on Ibex Investors's 13F filing for Q3 2018, filed 13 Nov 2018.